Research ArticleCLINICAL INVESTIGATIONS
Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial
Gregory A. Wiseman, Karel Pacak, Mary S. O'Dorisio, Donald R. Neumann, Alan D. Waxman, David A. Mankoff, Sherif I. Heiba, Aldo N. Serafini, Sabah S. Tumeh, Natalie Khutoryansky and Arnold F. Jacobson
Journal of Nuclear Medicine September 2009, 50 (9) 1448-1454; DOI: https://doi.org/10.2967/jnumed.108.058701
Gregory A. Wiseman
Karel Pacak
Mary S. O'Dorisio
Donald R. Neumann
Alan D. Waxman
David A. Mankoff
Sherif I. Heiba
Aldo N. Serafini
Sabah S. Tumeh
Natalie Khutoryansky

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 50, Issue 9
September 2009
Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial
Gregory A. Wiseman, Karel Pacak, Mary S. O'Dorisio, Donald R. Neumann, Alan D. Waxman, David A. Mankoff, Sherif I. Heiba, Aldo N. Serafini, Sabah S. Tumeh, Natalie Khutoryansky, Arnold F. Jacobson
Journal of Nuclear Medicine Sep 2009, 50 (9) 1448-1454; DOI: 10.2967/jnumed.108.058701
Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial
Gregory A. Wiseman, Karel Pacak, Mary S. O'Dorisio, Donald R. Neumann, Alan D. Waxman, David A. Mankoff, Sherif I. Heiba, Aldo N. Serafini, Sabah S. Tumeh, Natalie Khutoryansky, Arnold F. Jacobson
Journal of Nuclear Medicine Sep 2009, 50 (9) 1448-1454; DOI: 10.2967/jnumed.108.058701
Jump to section
Related Articles
Cited By...
- Tumor Dose-Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET
- Long-term disease-free survival after MIBG therapy for metastatic pheochromocytoma
- Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine
- Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
- Imaging of Pheochromocytoma and Paraganglioma
- Norepinephrine Transporter as a Target for Imaging and Therapy
- Phaeochromocytoma presenting as an acute coronary syndrome
- Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1
- Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters
- MANAGEMENT OF ENDOCRINE DISEASE: Clinical management of paragangliomas
- False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease
- Survey of the Performance of Commercial Dose Calibrators for Measurement of 123I Activity
- Pheochromocytomas detected by biochemical screening in predisposed subjects are associated with lower prevalence of clinical and biochemical manifestations and smaller tumors than pheochromocytomas detected by signs and symptoms